1. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.
Lancet 2004;364:2106-2112.
2. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica.
Neurology 2006;66:1485-1489.
3. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica.
Lancet Neurol 2007;6:805-815.
4. Pugliatti M, Rosati G, Carton H, Riise T, Drulovic J, Vécsei L, et al. The epidemiology of multiple sclerosis in Europe.
Eur J Neurol 2006;13:700-722.
5. Wingerchuk DM, Carter JL. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
Mayo Clin Proc 2014;89:225-240.
6. Compston A. Genetic epidemiology of multiple sclerosis.
J Neurol Neurosurg Psychiatry 1997;62:553-561.
7. Kim NH, Kim HJ, Cheong HK, Kim BJ, Lee KH, Kim EH, et al. Prevalence of multiple sclerosis in Korea.
Neurology 2010;75:1432-1438.
8. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome).
Neurology 1999;53:1107-1114.
9. Pandit L, Asgari N, Apiwattanakul M, Palace J, Paul F, Leite MI, et al. Demographic and clinical features of neuromyelitis optica: A review.
Mult Scler 2015;21:845-853.
10. Pittock SJ, Lucchinetti CF. Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later.
Ann N Y Acad Sci 2016;1366:20-39.
11. Siritho S, Nakashima I, Takahashi T, Fujihara K, Prayoonwiwat N. AQP4 antibody-positive Thai cases: clinical features and diagnostic problems.
Neurology 2011;77:827-834.
12. Kim SM, Waters P, Woodhall M, Yang JW, Yang H, Kim JE, et al. Characterization of the spectrum of Korean inflammatory demyelinating diseases according to the diagnostic criteria and AQP4-Ab status.
BMC Neurol 2014;14:93.
13. Etemadifar M, Nasr Z, Khalili B, Taherioun M, Vosoughi R. Epidemiology of neuromyelitis optica in the world: a systematic review and meta-analysis.
Mult Scler Int 2015;2015:174720.
14. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols.
Ann Neurol 1983;13:227-231.
15. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.
Ann Neurol 2001;50:121-127.
16. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria".
Ann Neurol 2005;58:840-846.
17. Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, Miller DH, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.
Neurology 2006;67:1242-1249.
18. Beck RW. The Optic Neuritis Treatment Trial.
Arch ophthalmol 1988;106:1051-1053.
19. Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial.
Lancet 2009;374:1503-1511.
20. Montalban X, Tintore M, Swanton J, Barkhof F, Fazekas F, Filippi M, et al. MRI criteria for MS in patients with clinically isolated syndromes.
Neurology 2010;74:427-434.
21. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel.
J Exp Med 2005;202:473-477.
22. Kim W, Park MS, Lee SH, Kim SH, Jung IJ, Takahashi T, et al. Characteristic brain magnetic resonance imaging abnormalities in central nervous system aquaporin-4 autoimmunity.
Mult Scler 2010;16:1229-1236.
23. Kim W, Kim SH, Lee SH, Li XF, Kim HJ. Brain abnormalities as an initial manifestation of neuromyelitis optica spectrum disorder.
Mult Scler 2011;17:1107-1112.
24. Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.
Neurology 2015;85:177-189.
25. Kim HJ, Paul F, Lana-Peixoto MA, Tenembaum S, Asgari N, Palace J, et al. MRI characteristics of neuromyelitis optica spectrum disorder: an international update.
Neurology 2015;84:1165-1173.
26. Popescu BF, Lennon VA, Parisi JE, Howe CL, Weigand SD, Cabrera-Gómez JA, et al. Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications.
Neurology 2011;76:1229-1237.
27. Weinshenker BG, Wingerchuk DM, Vukusic S, Linbo L, Pittock SJ, Lucchinetti CF, et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis.
Ann Neurol 2006;59:566-569.
28. Misu T, Fujihara K, Nakashima I, Sato S, Itoyama Y. Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica.
Neurology 2005;65:1479-1482.
29. Takahashi T, Miyazawa I, Misu T, Takano R, Nakashima I, Fujihara K, et al. Intractable hiccup and nausea in neuromyelitis optica with anti-aquaporin-4 antibody: a herald of acute exacerbations.
J Neurol Neurosurg Psychiatry 2008;79:1075-1078.
30. Tackley G, Kuker W, Palace J. Magnetic resonance imaging in neuromyelitis optica.
Mult Scler 2014;20:1153-1164.
31. Flanagan EP, Weinshenker BG, Krecke KN, Lennon VA, Lucchinetti CF, McKeon A, et al. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders.
JAMA Neurol 2015;72:81-87.
32. Nakamura M, Miyazawa I, Fujihara K, Nakashima I, Misu T, Watanabe S, et al. Preferential spinal central gray matter involvement in neuromyelitis optica. An MRI study.
J Neurol 2008;255:163-170.
33. Pekcevik Y, Mitchell CH, Mealy MA, Orman G, Lee IH, Newsome SD, et al. Differentiating neuromyelitis optica from other causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging.
Mult Scler 2015;22:302-311.
34. Yonezu T, Ito S, Mori M, Ogawa Y, Makino T, Uzawa A, et al. “Bright spotty lesions” on spinal magnetic resonance imaging differentiate neuromyelitis optica from multiple sclerosis.
Mult Scler 2014;20:331-337.
35. Hyun JW, Kim SH, Jeong IH, Lee SH, Kim HJ. Bright spotty lesions on the spinal cord: an additional MRI indicator of neuromyelitis optica spectrum disorder?
J Neurol Neurosurg Psychiatry 2015;86:1280-1282.
36. Kim SM, Go MJ, Sung JJ, Park KS, Lee KW. Painful tonic spasm in neuromyelitis optica: incidence, diagnostic utility, and clinical characteristics.
Arch Neurol 2012;69:1026-1031.
37. Usmani N, Bedi G, Lam BL, Sheremata WA. Association between paroxysmal tonic spasms and neuromyelitis optica.
Arch Neurol 2012;69:121-124.
38. Storoni M, Davagnanam I, Radon M, Siddiqui A, Plant GT. Distinguishing optic neuritis in neuromyelitis optica spectrum disease from multiple sclerosis: a novel magnetic resonance imaging scoring system.
J Neuroophthalmol 2013;33:123-127.
39. Khanna S, Sharma A, Huecker J, Gordon M, Naismith RT, Van Stavern GP. Magnetic resonance imaging of optic neuritis in patients with neuromyelitis optica versus multiple sclerosis.
J Neuroophthalmol 2012;32:216-220.
40. Fernandes DB, Ramos Rde I, Falcochio C, Apostolos-Pereira S, Callegaro D, Monteiro ML. Comparison of visual acuity and automated perimetry findings in patients with neuromyelitis optica or multiple sclerosis after single or multiple attacks of optic neuritis.
J Neuroophthalmol 2012;32:102-106.
41. Kremer S, Renard F, Achard S, Lana-Peixoto MA, Palace J, Asgari N, et al. Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder.
JAMA Neurol 2015;72:815-822.
42. Ratchford JN, Quigg ME, Conger A, Frohman T, Frohman E, Balcer LJ, et al. Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies.
Neurology 2009;73:302-308.
43. Kim W, Kim SH, Huh SY, Kim HJ. Brain abnormalities in neuromyelitis optica spectrum disorder.
Mult Scler Int 2012;2012:735486.
44. Huh SY, Min JH, Kim W, Kim SH, Kim HJ, Kim BJ, et al. The usefulness of brain MRI at onset in the differentiation of multiple sclerosis and seropositive neuromyelitis optica spectrum disorders.
Mult Scler 2014;20:695-704.
45. Matthews L, Marasco R, Jenkinson M, Küker W, Luppe S, Leite MI, et al. Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution.
Neurology 2013;80:1330-1337.
46. Sinnecker T, Dorr J, Pfueller CF, Harms L, Ruprecht K, Jarius S, et al. Distinct lesion morphology at 7-T MRI differentiates neuromyelitis optica from multiple sclerosis.
Neurology 2012;79:708-714.
47. Quinn MP, Kremenchutzky M, Menon RS. Venocentric Lesions: An MRI Marker of MS?
Front Neurol 2013;4:98.
48. Ciccarelli O, Thomas DL, De Vita E, Wheeler-Kingshott CA, Kachramanoglou C, Kapoor R, et al. Low myo-inositol indicating astrocytic damage in a case series of neuromyelitis optica.
Ann Neurol 2013;74:301-305.
49. Jarius S, Paul F, Franciotta D, Ruprecht K, Ringelstein M, Bergamaschi R, et al. Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures.
J Neurol Sci 2011;306:82-90.
50. Dobson R, Ramagopalan S, Davis A, Giovannoni G. Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude.
J Neurol Neurosurg Psychiatry 2013;84:909-914.
51. Bergamaschi R, Tonietti S, Franciotta D, Candeloro E, Tavazzi E, Piccolo G, et al. Oligoclonal bands in Devic's neuromyelitis optica and multiple sclerosis: differences in repeated cerebrospinal fluid examinations.
Mult Scler 2004;10:2-4.